Arabic Arabic English English French French German German

Media Call: Pfizer-BioNTech COVID-19 Vaccine Actions – 1/3/2022

Join us for a media call to discuss the FDA’s amendment to the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to:
– Expand the use of a single booster dose to include use in individuals 12 through 15 years of age.
– Shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months.
– Allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.

Acting FDA Commissioner Dr. Janet Woodcock and FDA’s Center for Biologics Evaluation and Research Director Dr. Peter Marks will be taking questions.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Stem cells instead of drugs? Trial is testing a way to help strengthen transplant patients’ immune systems

Next Post

American Academy of Orthopaedic Surgeons updates guideline for managing hip fracture in seniors

Related Posts